Avalo Therapeutics Enters Material Agreement
Ticker: AVTX · Form: 8-K · Filed: Apr 28, 2026 · CIK: 0001534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, Inc. (AVTX) |
| Form Type | 8-K |
| Filed Date | Apr 28, 2026 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, regulation-fd, exhibits
TL;DR
Avalo Therapeutics signed a big deal, check the exhibits for details.
AI Summary
On April 26, 2026, Avalo Therapeutics, Inc. entered into a material definitive agreement related to a milestone buyout option. The filing also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
This filing indicates a significant development in Avalo Therapeutics' business operations, potentially impacting its future strategic direction and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks and obligations for a company.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Filer
- 0001534120 (company) — CIK Number
- 2026-04-28 (date) — Filing Date
- 2026-04-26 (date) — Period of Report
FAQ
What type of material definitive agreement did Avalo Therapeutics enter into?
Avalo Therapeutics entered into a material definitive agreement related to a milestone buyout option, as indicated by the filing of EX-10.1.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 28, 2026.
What is the CIK number for Avalo Therapeutics, Inc.?
The CIK number for Avalo Therapeutics, Inc. is 0001534120.
What are the main items disclosed in this 8-K filing?
The main items disclosed are Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits).
What is the business address of Avalo Therapeutics, Inc.?
The business address is 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2026 regarding Avalo Therapeutics, Inc. (AVTX).